Eli Lilly and Company (LLY) Stock Analysis
Eli Lilly and Company (LLY) is a multinational pharmaceutical manufacturer with a portfolio spanning diabetes, oncology, immunology, and neurology. Investors research LLY for exposure to high-growth segments like GLP-1 obesity treatments (Zepbound, Mounjaro) and its established insulin franchise, alongside concerns about valuation and competitive pressures.
Get a full AI research report on LLY
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Eli Lilly and Company do?
Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products globally, with major revenue streams from cardiometabolic products (insulin, Mounjaro, Trulicity, Jardiance), oncology treatments (Verzenio, Cyramza, Retevmo), and immunology drugs. The company operates across the United States, Europe, China, Japan, and other international markets, generating revenue through patent-protected branded medications and benefiting from high gross margins typical of the pharmaceutical industry.
Bull case
- ✓Mounjaro and Zepbound address the rapidly expanding obesity and type 2 diabetes markets, with Mounjaro showing strong uptake and potential for significant revenue growth as obesity treatment adoption accelerates.
- ✓Gross margin of 83.4% and operating margin of 54.2% demonstrate pricing power and operational efficiency, providing substantial cash flow for R&D and shareholder returns despite competitive pressures.
- ✓Diversified portfolio across multiple therapeutic areas (cardiometabolic, oncology, immunology, neurology) reduces dependence on any single drug and spreads regulatory and commercial risk.
- ✓Forward P/E of 24.4x is materially lower than trailing P/E of 38.8x, suggesting market expectations for earnings growth that could justify current valuation if pipeline drugs and Mounjaro adoption meet guidance.
Bear case
- ✗Trailing P/E of 38.8x reflects elevated valuation relative to historical pharma averages, leaving limited margin for error if growth expectations disappoint or competitive biosimilars erode pricing.
- ✗High debt-to-equity ratio of 162.1% indicates substantial leverage, which constrains financial flexibility and increases refinancing risk in a rising interest rate environment.
- ✗Quick ratio of 0.68x suggests potential near-term liquidity constraints relative to current liabilities, raising questions about the company's ability to meet short-term obligations without asset sales or financing.
- ✗Mounjaro and Zepbound face increasing competition from other GLP-1 agonists (Novo Nordisk's Ozempic/Wegovy, Amgen's MariTide), and biosimilar erosion of insulin franchise could pressure margins and market share.
- ✗Regulatory and patent risks are inherent in pharma; loss of exclusivity on key drugs or adverse safety findings could materially impact revenue and stock performance.
LLY valuation & financial health
Eli Lilly trades at a trailing P/E of 38.8x with a forward P/E of 24.4x, suggesting the market is pricing in meaningful earnings growth. The PEG ratio of 1.14 indicates valuation is moderate relative to expected growth, though still elevated in absolute terms. With a gross margin of 83.4% and operating margin of 54.2%, the company demonstrates strong profitability and pricing power. However, the debt-to-equity ratio of 162.1% and quick ratio of 0.68x reveal significant leverage and potential near-term liquidity tightness, offsetting the strength in profitability. Return on equity of 102.3% is exceptionally high but partly reflects the capital structure; return on assets of 20.4% is more sustainable. The 0.6% dividend yield and 21.7% payout ratio suggest the company prioritizes reinvestment and acquisitions over income distribution.
The bottom line
Eli Lilly presents a classic growth-at-a-premium-price profile, with compelling secular tailwinds from obesity treatment adoption and a diversified pharma portfolio, balanced against elevated valuation multiples and material financial leverage. Key factors to weigh include whether Mounjaro and Zepbound can sustain market share and pricing in an increasingly competitive GLP-1 landscape, the company's ability to service and refinance its debt, and whether forward earnings growth justifies the 24x forward multiple. Investors should monitor quarterly Mounjaro uptake trends, pipeline advancement, debt reduction progress, and competitive dynamics in obesity and diabetes treatment before forming a conviction.
Frequently asked questions
What does Eli Lilly and Company do?
Eli Lilly discovers, develops, manufactures, and markets pharmaceutical products across cardiometabolic health (insulin, Mounjaro, Trulicity), oncology (Verzenio, Cyramza), immunology, and neurology. The company operates globally and generates revenue through patent-protected branded medications sold to healthcare providers and patients.
Is LLY overvalued?
LLY trades at a trailing P/E of 38.8x and forward P/E of 24.4x. The forward multiple is lower and the PEG ratio of 1.14 suggests moderate valuation relative to growth, but absolute multiples remain elevated compared to historical pharma averages, leaving limited room for disappointment.
What are Eli Lilly's main revenue drivers?
Key revenue drivers include Mounjaro and Zepbound (GLP-1 treatments for diabetes and obesity), the insulin franchise (Humalog, Humulin, Basaglar), Trulicity and Jardiance (diabetes), and oncology products like Verzenio and Cyramza. Mounjaro is experiencing strong uptake and represents significant growth potential.
What are the main risks for LLY stock?
Key risks include elevated valuation multiples, high debt-to-equity ratio of 162.1%, competition from other GLP-1 agonists, biosimilar erosion of insulin products, regulatory and patent risks, and potential near-term liquidity constraints reflected in a quick ratio of 0.68x.
Does Eli Lilly pay a dividend?
Yes, LLY pays a dividend with a yield of 0.6% and a payout ratio of 21.7%, indicating the company prioritizes reinvestment in R&D and acquisitions over income distribution to shareholders.
How financially healthy is Eli Lilly?
LLY demonstrates strong profitability with 83.4% gross margin and 54.2% operating margin, but carries substantial debt (debt-to-equity of 162.1%) and has a quick ratio of 0.68x, suggesting leverage and potential near-term liquidity tightness that warrant monitoring.
Research LLY with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.